In gastric cancer, higher TRIM21/Ro52 expression not only is correlated with a lower recurrence and a better 5-year survival rate but also enhances the chemosensitivity of the tumor cells to apatinib, an FDA-proved treatment for chemotherapy-refractory advanced gastric cancer [41, 49]. Here, TRIM21 is linked to gastric cancer.